NurExone Biologic Inc. has appointed David Stolick to its Board of Directors, effective July 28, 2026, strengthening its governance as it advances exosome-based regenerative therapies. Stolick succeeds the late James "Jay" Richardson, whose leadership shaped the company during its formative years. The appointment brings extensive finance, capital markets, and M&A experience to the board, supporting NurExone’s growth strategy and disciplined execution.

Stolick previously served as VP of Finance at V-Wave Ltd., a U.S.-Israeli medical device company acquired by Johnson & Johnson in October 2024. He also held CFO roles at Exalenz Bioscience and BrainStorm Cell Therapeutics, and served as Corporate Controller at M-Systems. A Certified Public Accountant with a B.A. in Economics and Accounting from Ben-Gurion University, Stolick stated he looks forward to contributing his financial expertise to support long-term shareholder value.

In a separate corporate update, NurExone entered into an investor awareness engagement with Cashu Technologies Pty Ltd. ("Cashu"), an arm’s length party, for retail investor awareness services. The term ends no later than December 31, 2026, and is terminable by either party on 30 days’ notice. Cashu will receive US$2,500 per month for a monthly program, with an optional one-time fee between US$20,000 and US$40,000 for an additional campaign if elected by the company. Consideration is payable solely in cash, with no securities issued.

The engagement remains subject to acceptance by the TSX Venture Exchange. To the knowledge of NurExone, Cashu holds no direct or indirect interest in the company’s securities and has no right or intent to acquire such an interest. Yoram Drucker, Chairman of the Board, noted that Stolick understands what it takes to move from innovative technology to disciplined execution, adding that his perspective will be an important addition as the company continues to grow.

What the Numbers Show

The financial structure of the investor awareness engagement reflects a low fixed-cost model with scalable optional spending. The mandatory US$2,500 monthly fee ensures baseline retail outreach, while the optional US$20,000–US$40,000 campaign allows NurExone to amplify visibility selectively without committing upfront capital. This flexibility aligns with the company’s preclinical-stage profile, where capital preservation remains critical alongside regulatory milestones for its lead product, ExoPTEN.

NurExone Biologic Inc.'s wholly-owned subsidiary, Exo-Top Inc., has entered into a binding Memorandum of Understanding (MOU) with ExoLyra LLC to distribute naïve mesenchymal stem cell (MSC)-derived exosome products in Mexico. The agreement establishes a structured commercial foothold for Exo-Top by outlining specific financial and operational terms intended for incorporation into a Definitive Agreement within 45 calendar days. This arrangement marks Exo-Top's first structured commercial entry into the naïve exosome sector.

Proposed Agreement Targets Mexico And Broader Expansion

Under the MOU, ExoLyra would receive exclusive rights to market, import, and sell Exo-Top's exosome products in Mexico. The agreement also provides ExoLyra with a preferential right to negotiate exclusive distribution rights for Brazil and Panama for two years. Outside Mexico, the proposed agreement would grant ExoLyra non-exclusive global sales rights, subject to customer pre-clearance and customer-specific exclusivity provisions tied to purchase thresholds. Per-customer exclusivity may be triggered for pre-cleared international customers that purchase at least 90 units within a 90-day period, subject to annual maintenance of at least 150 units per year.

Financial Commitments And Performance Requirements

The proposed Mexico exclusivity period would initially span three years, with extension options that could bring the total term to 10 years if performance requirements are met. ExoLyra has agreed to fund initial distribution and market penetration efforts with available capital of at least $800,000, including licensing fees. The agreement calls for a non-refundable territorial exclusivity fee totaling $180,000, consisting of a $40,000 payment upon signing the definitive agreement and an additional $140,000 payment once products are ready for commercial shipment. Beginning in the fourth year, Exo-Top would also be entitled to an annual sales maintenance fee of $100,000.

Minimum Purchase Thresholds And Regulatory Responsibilities

To retain exclusivity in Mexico, ExoLyra must satisfy minimum annual purchase commitments, beginning with 20,000 units during the first 18 months, increasing to 35,000 units in Year 2, 50,000 units in Year 3, and 60,000 units annually from Year 4 onward. These commitments are subject to a 5% annual growth escalator up to a minimum performance ceiling of 70,000 units per year. At least half of those annual minimum purchases must be distributed within Mexico. ExoLyra would assume responsibility for regulatory compliance, including marketing, importation, distribution, labeling, and product classification requirements across active territories. The MOU also contemplates a 120-day cure period for financial or volumetric deficiencies before Exo-Top may convert the Mexico license to non-exclusive status or void it.